Added to YB: 2025-12-22
Pitch date: 2025-12-18
GANX [bullish]
Gain Therapeutics, Inc.
+20.8%
current return
Author Info
Clinical Catalysts breaks down the science and strategy behind pharma market movers. Sign up for the newsletter.
Company Info
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia.
Market Cap
$155.8M
Pitch Price
$2.38
Price Target
N/A
Dividend
N/A
EV/EBITDA
-8.49
P/E
-6.36
EV/Sales
N/A
Sector
Biotechnology
Category
growth
The Micro-Cap Biotech Using AI to Tackle Neurodegenerative Diseases at the Source - Gain Therapeutics, Inc.
GANX: Clinical-stage biotech targeting Parkinson's via GCase enzyme restoration. Phase 1b showed 100% reduction in CSF GluSph biomarker, well-tolerated safety. $8.8M cash through 2026, IND submission Q4 2025. No approved GCase therapies exist. Risk: early biomarker data, funding needs for Phase 2.
Read full article (5 min)